- Home
- DNLI vs QURE Comparison
DNLI vs QURE Comparison
Compare DNLI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | QURE |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DNLI | QURE |
|---|---|---|
| Price | $18.95 | $24.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | $35.50 | ★ $60.30 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $54.76 |
| Revenue Next Year | $157.92 | $356.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.75 | $8.73 |
| 52 Week High | $27.30 | $51.72 |
Technical Indicators
Market Signals| Indicator | DNLI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 41.87 |
| Support Level | $17.75 | $24.00 |
| Resistance Level | $19.35 | $25.61 |
| Average True Range (ATR) | 0.77 | 1.33 |
| MACD | 0.21 | 1.14 |
| Stochastic Oscillator | 61.22 | 78.27 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.